HF
LABP

HRT Financial’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

HRT Financial’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,256
Closed -$26K – 3483
2022
Q4 		$26K Buy
+5,256
New +$20.1K ﹤0.01% 2158

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial's LABP Position: Q1 2023 in Review

HRT Financial sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q1 2023, closing a stake of 5,256 shares — an estimated $26K sold.

HRT Financial first reported a position in LABP in Q4 2022 and held it in 1 quarter. The position peaked at $26K in Q4 2022. 20 funds tracked by Wall St. Rank hold LABP as of Q1 2023.

  • HRT Financial reported no remaining Landos Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • HRT Financial sold 5,256 Landos Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $26K.
  • HRT Financial first reported a position in Landos Biopharma, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • HRT Financial's Landos Biopharma, Inc. Common Stock position peaked at $26K in Q4 2022.
  • 20 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.